Updates are available Correction dated 2024-10-24

Article History

Received: 23 November 2023

Accepted: 11 February 2024

First Online: 18 April 2024

Change Date: 24 October 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s40478-024-01787-y

Declarations

:

: Experiments including C57BL6/JCr mice were in compliance with the EU Directive 2010/63/EU under ECD code 2022–59 after approval by the Animal Ethics Committee of the University of Antwerp. The cerebellar tissue of a died nine-year-old child was a kind gift from the Institute Born-Bunge vzw IBB NeuroBioBank of the University of Antwerp under HMTA20210040 by the Ethics Committee of the Hospital Network Antwerp (ZNA) Middelheim and HogeBeuken, Antwerp, Belgium. Clinical information of a died six-year-old male carrying the heterozygous c.1676dupA/p.His559Glnfs*3 ADNP mutation was received under informed consent of the parents under B300201627322 and approved by the Ethics Committee of the Antwerp University Hospital, Antwerp, Belgium. HEK293T cells were purchased from ATCC at a low passage number with consistent use of cells below a passage number of 15. LCLs were generated from peripheral blood lymphocytes donated by consenting patients and guardians/physicians in the laboratory of Frank Kooy. Immortalized skin fibroblasts were generated by consenting patients and guardians/physicians in the laboratory of Frank Kooy.

: An written informed consent under for publication died six-year-old male carrying the heterozygous c.1676dupA/p.His559Glnfs*3 ADNP mutation was received by the mother (caregiver) and gives permission to the medical doctors of the Department of Medical Genetics, University Hospital Antwerp, to use photographs, biopsies and/or X-rays for medical reasons (discussion between colleagues, teaching, or publication in scientific papers). The Institute Born-Bunge vzw IBB NeuroBioBank of the University of Antwerp acknowledges publication in all oral presentations, written or press related releases related to the use of the cerebellar tissue of a died nine-year-old female. All patient-derived cell lines were obtained under a written informed consent for publication by the patients, their guardians, and the tending clinicians.

: We confirm that this study is reported in accordance with the ARRIVE guidelines ().

: Professor Dr. Em. Illana Gozes serves as VP drug development at ExoNavis Therapeutics LTD, clinically developing Davunetide.